Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect?

Tumori - 1 Dec 2022

Garajová Ingrid, Balsano Rita, Gelsomino Fabio, Leonardi Francesco

Abstract excerpt

BACKGROUND: Despite ongoing developments, pancreatic cancer remains one of the most difficult tumors to treat. Even the most effective chemotherapy regimens, only marginally improve the outcome of Pancreatic cancer patients, which rarely exceeds one year. A small subset of Pancreatic cancer patients, carriers of germline variants of BRCA1/2, are clinically relevant as therapeutic targets in pancreatic cancer,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to Germ-Line Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Ovarian Neoplasms

Share to Pancreatic Neoplasms

Share to Phthalazines

Share to Quality of Life

Source

Identifiers

PMID: 36299234
DOI: 10.1177/03008916221132589

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect?PMID 36299234Read ↗

An evaluation of olaparib for the treatment of pancreatic cancer.Semantic proximity Read ↗

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic CancerSemantic proximity Read ↗

BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment ParadigmsSemantic proximity Read ↗

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.Semantic proximity Read ↗

Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53Semantic proximity Read ↗

Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance Olaparib: Two case reports and review of the literature.Semantic proximity Read ↗

Emerging strategies in BRCA-positive pancreatic cancer.Semantic proximity Read ↗

Clinical characterization of patients with gBRCA1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study.Semantic proximity Read ↗

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA VariantsSemantic proximity Read ↗

Pancreatic cancer: BRCA mutation and personalized treatment.Semantic proximity Read ↗

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applicationsSemantic proximity Read ↗

Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.